Earlier this month, Grey Wolf Therapeutics presented at both the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the Neoantigen Based Therapies Summit.
The Neoantigen Based Therapies Summit took place between 3-5th November 2020. Dr. Peter Joyce, CEO & Co-founder of Grey Wolf Therapeutics, presented the data that has led to the nomination of a candidate, first-in-class ERAP1 inhibitor that is currently progressing through non-clinical development. Starting with ERAP1 inhibition as a concept, Dr. Joyce explained how Grey Wolf has been able to prove out the four corners of ERAP1 biology; target engagement, antigen modulation, T-cell response and tumour growth inhibition.
In October, Grey Wolf was delighted to find out that their abstract had been selected for an oral presentation at SITC 2020 (10-15th November). The presentation formed part of the Combinatorial Therapies session, chaired by Charlotte E. Ariyan, MD, PhD (Memorial Sloan Kettering Cancer Center) and Silvia Formenti, MD (Weill Cornell Medicine) on Wednesday 11th November. The team presented new data which demonstrates that ERAP1 inhibition has the potential to be a transformative therapeutic agent that could be used as monotherapy or in combination with other immunotherapies such as checkpoint blockade.
The accompanying poster is number 446 and is available for download here.
To keep up to date with the latest news from Grey Wolf Therapeutics, follow us on LinkedIn. If you have a question for the Grey Wolf team, please email email@example.com.